The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Domiati-Saad, R.
Right arrow Articles by Justement, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Domiati-Saad, R.
Right arrow Articles by Justement, L. B.

The Journal of Immunology, Vol 151, Issue 11 5936-5947, Copyright © 1993 by American Association of Immunologists


ARTICLES

Administration of anti-CD45 mAb specific for a B cell-restricted epitope abrogates the B cell response to a T-dependent antigen in vivo

R Domiati-Saad, EW Ogle and LB Justement
Department of Microbiology, University of Texas Medical Branch, Galveston 77555-1019.

CD45 is a receptor-like protein tyrosine phosphatase expressed exclusively by cells of the hemopoietic lineage. Studies in vitro involving treatment of B cells with anti-CD45 mAb have demonstrated that ligand binding to CD45 alters the cell's response to various activation/differentiation stimuli. In general anti-CD45 treatment has been shown to exert an inhibitory effect on early activation events resulting in the failure of quiescent B cells to enter the cell cycle. These studies suggest that CD45 acts as an important regulatory molecule in vitro, that controls B cell function. In contrast, little is known concerning the role that CD45 plays in vivo regarding regulation of B cell activation and differentiation in response to T- dependent Ag. In our study the anti-CD45 mAb RA3.6B2, which recognizes a B cell-restricted epitope, was used to examine this question. Administration of anti-CD45 mAb in vivo was found to inhibit the proliferative response of splenocytes when stimulated with B cell-, but not T cell-specific mitogens. Immunization with the T-dependent Ag FITC- KLH in the presence of increasing amounts of anti-CD45 mAb resulted in a significant, dose-dependent inhibition of the plaque-forming cell response. Additionally, anti-CD45 mAb inhibited the production of FITC- specific serum antibodies indicating that the effect was systemic. Finally, anti-CD45 mAb appeared to exert a maximal effect at earlier time points, within 48 h of Ag administration, suggesting that B cell activation was primarily affected. These results provide evidence to support the conclusion that CD45 is an important regulatory molecule that is involved in the control of B cell activation in vivo.


This article has been cited by other articles:


Home page
J. Immunol.Home page
C. Zhou, A. Saxon, and K. Zhang
Human Activation-Induced Cytidine Deaminase Is Induced by IL-4 and Negatively Regulated by CD45: Implication of CD45 as a Janus Kinase Phosphatase in Antibody Diversification
J. Immunol., February 15, 2003; 170(4): 1887 - 1893.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.